Progyny (NASDAQ:PGNY) Board Authorizes Share Buyback Plan

Progyny (NASDAQ:PGNY) announced that its board has initiated a share buyback plan on Tuesday, May 26th, RTT News reports. The company plans to repurchase $200.00 million in outstanding shares. This repurchase authorization allows the company to reacquire up to 10.3% of its shares through open market purchases. Shares repurchase plans are often a sign that the company’s leadership believes its stock is undervalued.

Progyny Stock Performance

Shares of NASDAQ:PGNY traded up $0.17 during trading on Tuesday, hitting $25.05. 1,107,662 shares of the stock were exchanged, compared to its average volume of 1,711,836. Progyny has a 1-year low of $16.10 and a 1-year high of $28.75. The company has a market capitalization of $1.96 billion, a price-to-earnings ratio of 32.53, a price-to-earnings-growth ratio of 1.32 and a beta of 0.91. The company’s fifty day simple moving average is $19.36 and its 200-day simple moving average is $22.15.

Progyny (NASDAQ:PGNY) last announced its quarterly earnings data on Thursday, May 7th. The company reported $0.50 earnings per share for the quarter, topping the consensus estimate of $0.26 by $0.24. The company had revenue of $328.50 million for the quarter, compared to analyst estimates of $326.47 million. Progyny had a return on equity of 13.34% and a net margin of 5.23%.Progyny’s revenue for the quarter was down 26.4% compared to the same quarter last year. During the same quarter last year, the firm earned $0.17 EPS. Progyny has set its FY 2026 guidance at 1.980-2.09 EPS and its Q2 2026 guidance at 0.500-0.53 EPS. On average, research analysts forecast that Progyny will post 1.12 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

PGNY has been the topic of a number of research analyst reports. Jefferies Financial Group reaffirmed a “buy” rating and issued a $30.00 target price on shares of Progyny in a report on Friday, March 6th. BTIG Research lowered their target price on Progyny from $35.00 to $30.00 and set a “buy” rating on the stock in a report on Thursday, March 5th. Weiss Ratings reissued a “hold (c)” rating on shares of Progyny in a report on Friday, March 27th. Zacks Research raised Progyny from a “hold” rating to a “strong-buy” rating in a report on Thursday, May 7th. Finally, Wall Street Zen raised Progyny from a “hold” rating to a “buy” rating in a report on Saturday, April 18th. One investment analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $29.55.

Insider Activity at Progyny

In related news, COO Melissa B. Cummings sold 9,578 shares of the business’s stock in a transaction on Tuesday, May 19th. The stock was sold at an average price of $25.00, for a total value of $239,450.00. Following the sale, the chief operating officer owned 73,371 shares of the company’s stock, valued at $1,834,275. The trade was a 11.55% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Allison Swartz sold 4,657 shares of the business’s stock in a transaction on Tuesday, March 3rd. The shares were sold at an average price of $17.40, for a total value of $81,031.80. Following the completion of the sale, the executive vice president directly owned 89,879 shares in the company, valued at approximately $1,563,894.60. This represents a 4.93% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 25,308 shares of company stock valued at $579,977 in the last 90 days. 9.90% of the stock is owned by corporate insiders.

Progyny Company Profile

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.